Valink Therapeutics
Discovering bispecific antibody drug-conjugates (BsADC) against cancer
Valink Therapeutics develops next generation antibody-based therapeutics. We identify novel mechanism of action from known targets by incorporating multiple antibody modifications at once, rapidly and scalable generating complex drug candidates (bi-/multispecificity, multivalency and drug-conjugation in a single discovery process). Our research focus is on solid tumours poorly addressed by immunotherapy.
- Website
- valinktx.com
- City
- Boston
- Country
- United States
- YC batch
- Winter 2021
- Team
- 15 people
- Stage
- Early stage
- AI-native
- No
More Health & bio in Boston
WHOOP$10.1bn
Wearable technology. Valued at $10.1bn (March 2026).
Ginkgo BioworksHiring
Our mission is to make biology easier to engineer.
Modern HealthHiring
A mental health benefits platform for employers.
TetraScience
The only R&D data cloud for life sciences
OpenBiome
A nonprofit stool bank enabling access to fecal transplants.
SiPhox HealthHiring
At-Home health monitoring with silicon photonic chips for data centers
Claim this profile
Free and instant: prove you run valinktx.com and edit the profile yourself.
- Your logo, office address and founder photos
- The ✓ Verified mark next to Valink Therapeutics across the site
- Open roles listed on the Hiring board
- A followed link back to your website
A rank card with Valink Therapeutics's standing on Labspie, or a simple badge. Both link to this profile and update themselves.
